Amgen to Webcast 2024 Financial Results

5dabc53fc228786bc0ea8be435559524 AMGEN ANNOUNCES WEBCAST OF 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

THOUSAND OAKS, Calif., Jan. 31, 2025 — Amgen (NASDAQ:AMGN) will release its 2024 fourth-quarter and full-year financial results on February 4, 2025, after the U.S. markets close. A subsequent conference call with investors is scheduled for 4:30 p.m. ET. Amgen’s chairman and CEO, Robert A. Bradway, and other senior executives will participate.

This conference call will be webcast live and accessible to the media, investors, and the public.

This webcast, along with other management presentations at investor and medical conferences, is available on Amgen’s investor relations website. Details on timing, access, and webcast links are listed on Amgen’s Investor Relations Events Calendar. A replay will be archived for at least 90 days.

About Amgen
Amgen develops, manufactures, and provides innovative medicines to patients battling serious illnesses. Founded over 40 years ago, Amgen is a biotechnology leader, leveraging technology and genetic data for advancements. Amgen’s extensive pipeline expands upon its existing treatments for cancer, cardiovascular disease, osteoporosis, inflammatory conditions, and rare diseases.

In 2024, Amgen received recognition as one of Fast Company’s “World’s Most Innovative Companies” and one of Forbes’ “America’s Best Large Employers.” Amgen is a Dow Jones Industrial Average® component and a member of the Nasdaq-100 Index®, representing leading non-financial companies on the Nasdaq.

For more information, visit and follow Amgen on , , , and .

CONTACT: Amgen, Thousand Oaks
Elissa Snook, 609-251-1407 (media)
Justin Claeys, 805-313-9775 (investors) 

Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/)

 

SOURCE Amgen

elong